Details for Patent: 8,927,540

Which drugs does patent 8,927,540 protect, and when does it expire?

Patent 8,927,540 protects TEPMETKO and is included in one NDA.

This patent has seventy-nine patent family members in thirty-six countries.

Summary for Patent: 8,927,540

Title:	Pyridazinone derivatives
Abstract:	Compounds of the formula (I), in which R1, R2, R3, R4, R4′, have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumors.
Inventor(s):	Dieter Dorsch, Frank Stieber, Oliver Schadt, Andree Blaukat
Assignee:	Merck Patent GmbH
Application Number:	US13/785,580
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,927,540

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Emd Serono Inc	TEPMETKO	tepotinib hydrochloride	TABLET;ORAL	214096-001	Feb 3, 2021		RX	Yes	Yes	8,927,540					TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB

Foreign Priority and PCT Information for Patent: 8,927,540

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	10 2007 032 507	Jul 12, 2007

International Family Members for US Patent 8,927,540

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2164843		C02164843/01	Switzerland
European Patent Office	2164843		301176	Netherlands
European Patent Office	2164843		PA2022009	Lithuania
European Patent Office	2164843		2022C/519	Belgium